Defence Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DTCFF research report →
Price Chart
About the company
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases.
- CEO
- Amie Phinney
- IPO
- 2021
- Employees
- 1,300
- HQ
- Montreal, QC, CA
Get TickerSpark's AI analysis on DTCFF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $12.94M
- P/E
- -2.27
- PEG
- 0.05
- P/S
- 0.00
- P/B
- 5.40
- EV/EBITDA
- -2.95
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -424.91%
- ROIC
- -94.19%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-69,654+0.0%
- Op Income
- $-4,820,494
- Net Income
- $-6,467,591-61.7%
- EPS
- $-0.10-92.7%
- OCF Growth
- -39.8%
- FCF Growth
- -53.3%
- 52W High
- $0.76
- 52W Low
- $0.15
- 50D MA
- $0.27
- 200D MA
- $0.35
- Beta
- 1.35
- RSI (14)
- 29
- Avg Volume
- 11.40K
No earnings-call transcripts are available for DTCFF yet.
- Free Float
- 89.8%
- Shares Outstanding
- 76.11M
- Float Shares
- 68.33M
Our DTCFF coverage
Recent articles, reports, and earnings notes.
No research on DTCFF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DTCFF report →Defence Therapeutics Invites Shareholders to Its December 10, 2026, Annual General Meeting and 2027 Strategic Update
newsfilecorp.com · Nov 16
Defence Therapeutics Announces Convertible Debenture Interest Payment
newsfilecorp.com · Oct 23
Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform
newsfilecorp.com · Oct 19
Defence Therapeutics Inc. (OTCMKTS:DTCFF) Stock Short Interest Report for September
defenseworld.net · Oct 12
Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates
newsfilecorp.com · Oct 1
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
newsfilecorp.com · Sep 29
Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities
newsfilecorp.com · Sep 28
Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
newsfilecorp.com · Sep 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.